Non-small-cell lung cancer mrna expression signature predicting response to adjuvant chemotherapy

Journal of Clinical Oncology

Volumn 28, Issue 29, 2010, Pages 4404-4407

  Xie, Yang ^a   Minna, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NAVELBINE; PEMETREXED; PROTEIN P53; RAS PROTEIN;

ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EDITORIAL; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 79951990737     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.0144     Document Type: Editorial

References (32)

1. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 22:621s, 2004 (suppl; abstr 7019)
2. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-smallcell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006 (Pubitemid 44283661)
3. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004 (Pubitemid 38501140)
4. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004 (Pubitemid 38101630)
5. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005 (Pubitemid 41007845)
6. Strauss GM, Herndon JE 2nd, Maddaus MA, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043-5051, 2008
7. Douillard J-Y: Adjuvant chemotherapy for non-small-cell lung cancer: It does not always fade with time. J Clin Oncol 28:3-5, 2010
8. Olaussen KA, Mountzios G, Soria JC: ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13:284-289, 2007 (Pubitemid 46847293)
9. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006 (Pubitemid 44343542)
10. Subramanian J, Simon R: Gene expression-based prognostic signatures in lung cancer: Ready for clinical use? J Natl Cancer Inst 102:464-474, 2010
11. Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808, 2007 (Pubitemid 46294612)
12. Tsao MS, Aviel-Ronen S, Ding K, et al: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25:5240-5247, 2007 (Pubitemid 350232256)
13. Loriot Y, Mordant P, Deutsch E, et al: Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 6:528-534, 2009
14. Zhu C-Q, Ding K, Strumpf D, et al: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 28:4417-4424, 2010
15. National Cancer Center Network: NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA, National Cancer Center Network, 2010. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
16. Minna JD, Girard L, Xie Y: Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol 25:4329-4336, 2007 (Pubitemid 350013833)
17. Xie Y, Minna JD: Predicting the future for people with lung cancer. Nat Med 14:812-813, 2008
18. Boutros PC, Lau SK, Pintilie M, et al: Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A 106:2824-2828, 2009
19. Lau SK, Boutros PC, Pintilie M, et al: Three-gene prognostic classifier for early-stage non-small-cell lung cancer. J Clin Oncol 25:5562-5569, 2007
20. Chen HY, Yu SL, Chen CH, et al: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11-20, 2007
21. Gordon GJ, Richards WG, Sugarbaker DJ, et al: A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 12:905-910, 2003 (Pubitemid 37151527)
22. Hsu YC, Yuan S, Chen HY, et al: A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer. Clin Cancer Res 15:7309-7315, 2009
23. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, et al: Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 14:822-827, 2008
24. Skrzypski M, Jassem E, Taron M, et al: Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res 14:4794-4799, 2008
25. Sun Z, Wigle DA, Yang P: Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 26:877-883, 2008 (Pubitemid 351398079)
26. Mandrekar SJ, Sargent DJ: Genomic advances and their impact on clinical trial design. Genome Med 1:69, 2009
27. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034, 2009
28. Mandrekar SJ, Grothey A, Goetz MP, et al: Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 5:317-325, 2005 (Pubitemid 41425609)
29. Jiang W, Freidlin B, Simon R: Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 99:1036-1043, 2007 (Pubitemid 47232604)
30. Mandrekar SJ, Sargent DJ: Predictive biomarker validation in practice: Lessons from real trials. Clin Trials [epub ahead of print on April 14, 2010]
31. Coombes KR, Wang J, Baggerly KA: Microarrays: Retracing steps. Nat Med 13:1276-1277; author reply 1277-1278, 2007
32. Rainer J, Sanchez-Cabo F, Stocker G, et al: CARMAweb: Comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Res 34:W498-W503, 2006 (Pubitemid 44529821)